Realistic expectations of prepulse inhibition in translational models for schizophrenia research.
BACKGROUND
Under specific conditions, a weak lead stimulus, or "prepulse", can inhibit the startling effects of a subsequent intense abrupt stimulus. This startle-inhibiting effect of the prepulse, termed "prepulse inhibition" (PPI), is widely used in translational models to understand the biology of brainbased inhibitory mechanisms and their deficiency in neuropsychiatric disorders. In 1981, four published reports with "prepulse inhibition" as an index term were listed on Medline; over the past 5 years, new published Medline reports with "prepulse inhibition" as an index term have appeared at a rate exceeding once every 2.7 days (n=678). Most of these reports focus on the use of PPI in translational models of impaired sensorimotor gating in schizophrenia. This rapid expansion and broad application of PPI as a tool for understanding schizophrenia has, at times, outpaced critical thinking and falsifiable hypotheses about the relative strengths vs. limitations of this measure.


OBJECTIVE
This review enumerates the realistic expectations for PPI in translational models for schizophrenia research, and provides cautionary notes for the future applications of this important research tool.


CONCLUSIONS
In humans, PPI is not "diagnostic"; levels of PPI do not predict clinical course, specific symptoms, or individual medication responses. In preclinical studies, PPI is valuable for evaluating models or model organisms relevant to schizophrenia, "mapping" neural substrates of deficient PPI in schizophrenia, and advancing the discovery and development of novel therapeutics. Across species, PPI is a reliable, robust quantitative phenotype that is useful for probing the neurobiology and genetics of gating deficits in schizophrenia.
Department of Psychiatry, UCSD School of Medicine, La Jolla, CA, 92093-0804, USA, nswerdlow@ucsd.edu.
Neal R
NR
Swerdlow
Martin
M
Weber
Ying
Y
Qu
Gregory A
GA
Light
David L
DL
Braff
D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D008960:Models, Psychological; D013216:Reflex, Startle / Q000187:drug effects* / Q000235:genetics / Q000502:physiology*; D012559:Schizophrenia / Q000188:drug therapy* / Q000235:genetics; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents